ガイドライン

(旧版)前立腺癌診療ガイドライン 2006年版

書誌情報
第3章 治療総論

 
参考文献

3 外科治療  *この項の文献番号は、「第4章外科治療」の文献番号と対応しています。

1) 中山健夫: EBM を用いた診療ガイドライン作成・活用ガイド.金原出版; 2004.
4) D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376-83.
5) Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy:oncological outcome during a 20-year period. J Urol 1999;161(1):163-8.
6) D'Amico AV:Predicting prostate-specific antigen recurrence established:now, who will survive? J Clin Oncol. 2002;20(15):3188-90.
7) Schild SE, Wong WW, Novicki DE, et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology. 1996;47(6):878-81.
8) Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154(6):2128-31.
9) Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7.
10) Scher HI. Management of prostate cancer after prostatectomy:treating the patient, not the PSA. JAMA. 1999 5;281(17):1642-5.
11) Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349(9056):906-10.
12) Graversen PH, Nielsen KT, Gasser TC, et al. Radical prostatectomy versus expectant primary treatment in stagesI and II prostatic cancer. A fifteen-year follow-up. Urology. 1990;36(6):493-8.
13) Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management:a retrospective analysis. Cancer. 2001:91(12):2302-14.
14) Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781-9.
15) Elgamal AA, Van Poppel HP, Van de Voorde WM, et al. Impalpable invisible stage T1c prostate cancer:characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol. 1997;157(1):244-50.
16) Oesterling JE, Suman VJ, Zincke H, et al. PSA-detected(clinical stage T1c or B0)prostate cancer. Pathologically significant tumors. Urol Clin North Am. 1993;20(4):687-93.
17) Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer:the Johns Hopkins experience with tumors found on transurethral resection(stages T1A and T1B)and on needle biopsy(stage T1C). J Urol. 1994;152:1721-9.
18) Gibbons RP. Total prostatectomy for clinically localized prostate cancer:long-term surgical results and current morbidity. NCI Monogr. 1988;(7):123-6.
19) Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24(2):395-406.
20) Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-42.
21) Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-5.
22) Zincke H, Oesterling JE, Blute ML, et al. Long-term(15 years)results after radical prostatectomy for clinically localized(stage T2c or lower)prostate cancer. J Urol. 1994;152:1850-7.
23) Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555-65.
24) Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
25) Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer:influence of concomitant pathological variables. J Urol. 2002;167(1):117-22.
26) van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer(T3)treated with radical prostatectomy as monotherapy. J Urol 1998;160(4):1392-7.
27) Alibhai SM, Naglie G, Nam R, et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21(17):3318-27.
28) Coen JJ, Zietman AL, Shipley WU. Prostatectomy or watchful waiting in prostate cancer. N Engl J Med. 2003;348(2):170-1;author reply.
29) Grimm MO, Kamphausen S, Hugenschmidt H, et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol. 2002;41(6):628-34;discussion 634.
30) Lu-Yao GL, McLerran D, Wasson J, et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269(20):2633-6.
31) Eastham JA, Kattan MW, Riedel E, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003;170:2292-5.
32) Van Poppel H, Collette L, Kirkali Z, et al. Quality control of radical prostatectomy:a feasibility study. Eur J Cancer. 2001;37(7):884-91.
33) Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer:5-year results. J Urol. 2002;167(1):112-6.
34) Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy:a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561-6.
35) Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170(3):791-4.
37) Salomon L, Anastasiadis AG, Levrel O, et al. Location of positive surgical margins after retropubic, perineal, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology. 2003;61(2):386-90.
38) Artibani W, Grosso G, Novara G, et al. Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur Urol. 2003;44(4):401-6.
39) Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group . BJU Int. 2001;87(1):61-5.
40) Lodding P, Bergdahl C, Nyberg M, et al. Inguinal hernia after radical retropubic prostatectomy for prostate cancer:a study of incidence and risk factors in comparison to no operation and lymphadenectomy. J Urol. 2001;166(3):964-7.
41) Lu-Yao GL, Albertsen P, Warren J, et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology. 1999;54(2):301-7.
42) Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol. 1998;160(2):454-8.
43) Abbou CC, Salomon L, Hoznek A, et al. Laparoscopic radical prostatectomy:preliminary results. Urology. 2000;55(5):630-4.
44) Guillonneau B, el-Fettouh H, Baumert H, et al. Laparoscopic radical prostatectomy:oncological evaluation after 1,000 cases a Montsouris Institute. J Urol. 2003;169(4):1261-6.
45) Rassweiler J, Sentker L, Seemann O, et al. Laparoscopic radical prostatectomy with the Heilbronn technique:an analysis of the first 180 cases. J Urol. 2001;166(6):2101-8.
46) Arai Y, Egawa S, Terachi T, et al. Morbidity of laparoscopic radical prostatectomy:summary of early multi-institutional experience in Japan. Int J Urol 2003;10(8):430-4.
47) Marcovich R, Wojno KJ, Wei JT, et al. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology. 2000;55(6):904-8.
48) Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer:the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354-60.
49) Sokoloff MH, Brendler CB:Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am. 2001;28(3):535-43.
50) Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(4):1063-8.
51) Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4.
52) Clark T, Parekh DJ, Cookson MS, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169(1):145-7;discussion 147-8.
53) Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy:high incidence of lymph node metastasis. J Urol. 2002;167(4):1681-6.
54) Freedland SJ, Sutter ME, Dorey F, et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365-9.
55) Leibman BD, Dillioglugil O, Wheeler TM, et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995;76(12):2530-4.
56) Lattouf JB, Saad F. Digital rectal exam following prostatectomy:is it still necessary with the use of PSA?. Eur Urol. 2003;43(4):333-6.
57) Niwakawa M, Tobisu K, Fujimoto H, et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int J Urol. 2002;9(3):134-40.
62) Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781-8.
63) Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163(3):845-50.
64) Duchesne GM, Dowling C, Frydenberg M, et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy:an Australian multicenter study. Urology. 2003;61(1):179-83.
65) Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002;60(2):281-7.
66) Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003;170(5):1833-7.
67) Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21(3):483-9.
68) Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59(1):51-60.
69) Schild SE. Radiation therapy(RT)after prostatectomy:The case for salvage therapy as opposed to adjuvant therapy. Int J Cancer. 2001 20;96(2):94-8.

書誌情報